Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OT6KH1WG)

• DOT Name: Neuroblast differentiation-associated protein AHNAK (AHNAK)
• Synonyms: Desmoyokin
• Gene Name: AHNAK
• Related Disease:
  Bladder transitional cell carcinoma
  Alzheimer disease
  Androgen insensitivity syndrome
  Autoimmune disease
  Breast cancer
  Breast carcinoma
  Clear cell renal carcinoma
  Glioma
  Hepatocellular carcinoma
  Metastatic malignant neoplasm
  Neoplasm
  Papillary renal cell carcinoma
  Renal cell carcinoma
  Rheumatoid arthritis
  Systemic lupus erythematosus
  Triple negative breast cancer
  Lung adenocarcinoma
  Lung cancer
  Lung carcinoma
  Lung neoplasm
  Adult glioblastoma
  Advanced cancer
  Asthma
  Carcinoma of liver and intrahepatic biliary tract
  Castration-resistant prostate carcinoma
  Glioblastoma multiforme
  Hepatitis B virus infection
  Liver cancer
  Matthew-Wood syndrome
  Melanoma
  Mesothelioma
  Metastatic melanoma
  Pancreatic adenocarcinoma
• UniProt ID: AHNK_HUMAN
• PDB ID: 4DRW; 4FTG; 4HRG
• Sequence:
  MEKEETTRELLLPNWQGSGSHGLTIAQRDDGVFVQEVTQNSPAARTGVVKEGDQIVGATI
  YFDNLQSGEVTQLLNTMGHHTVGLKLHRKGDRSPEPGQTWTREVFSSCSSEVVLSGDDEE
  YQRIYTTKIKPRLKSEDGVEGDLGETQSRTITVTRRVTAYTVDVTGREGAKDIDISSPEF
  KIKIPRHELTEISNVDVETQSGKTVIRLPSGSGAASPTGSAVDIRAGAISASGPELQGAG
  HSKLQVTMPGIKVGGSGVNVNAKGLDLGGRGGVQVPAVDISSSLGGRAVEVQGPSLESGD
  HGKIKFPTMKVPKFGVSTGREGQTPKAGLRVSAPEVSVGHKGGKPGLTIQAPQLEVSVPS
  ANIEGLEGKLKGPQITGPSLEGDLGLKGAKPQGHIGVDASAPQIGGSITGPSVEVQAPDI
  DVQGPGSKLNVPKMKVPKFSVSGAKGEETGIDVTLPTGEVTVPGVSGDVSLPEIATGGLE
  GKMKGTKVKTPEMIIQKPKISMQDVDLSLGSPKLKGDIKVSAPGVQGDVKGPQVALKGSR
  VDIETPNLEGTLTGPRLGSPSGKTGTCRISMSEVDLNVAAPKVKGGVDVTLPRVEGKVKV
  PEVDVRGPKVDVSAPDVEAHGPEWNLKMPKMKMPTFSTPGAKGEGPDVHMTLPKGDISIS
  GPKVNVEAPDVNLEGLGGKLKGPDVKLPDMSVKTPKISMPDVDLHVKGTKVKGEYDVTVP
  KLEGELKGPKVDIDAPDVDVHGPDWHLKMPKMKMPKFSVPGFKAEGPEVDVNLPKADVDI
  SGPKIDVTAPDVSIEEPEGKLKGPKFKMPEMNIKVPKISMPDVDLHLKGPNVKGEYDVTM
  PKVESEIKVPDVELKSAKMDIDVPDVEVQGPDWHLKMPKMKMPKFSMPGFKAEGPEVDVN
  LPKADVDISGPKVGVEVPDVNIEGPEGKLKGPKFKMPEMNIKAPKISMPDVDLHMKGPKV
  KGEYDMTVPKLEGDLKGPKVDVSAPDVEMQGPDWNLKMPKIKMPKFSMPSLKGEGPEFDV
  NLSKANVDISAPKVDTNAPDLSLEGPEGKLKGPKFKMPEMHFRAPKMSLPDVDLDLKGPK
  MKGNVDISAPKIEGEMQVPDVDIRGPKVDIKAPDVEGQGLDWSLKIPKMKMPKFSMPSLK
  GEGPEVDVNLPKADVVVSGPKVDIEAPDVSLEGPEGKLKGPKFKMPEMHFKTPKISMPDV
  DLHLKGPKVKGDVDVSVPKVEGEMKVPDVEIKGPKMDIDAPDVEVQGPDWHLKMPKMKMP
  KFSMPGFKGEGREVDVNLPKADIDVSGPKVDVEVPDVSLEGPEGKLKGPKFKMPEMHFKA
  PKISMPDVDLNLKGPKLKGDVDVSLPEVEGEMKVPDVDIKGPKVDISAPDVDVHGPDWHL
  KMPKVKMPKFSMPGFKGEGPEVDVKLPKADVDVSGPKMDAEVPDVNIEGPDAKLKGPKFK
  MPEMSIKPQKISIPDVGLHLKGPKMKGDYDVTVPKVEGEIKAPDVDIKGPKVDINAPDVE
  VHGPDWHLKMPKVKMPKFSMPGFKGEGPEVDMNLPKADLGVSGPKVDIDVPDVNLEAPEG
  KLKGPKFKMPSMNIQTHKISMPDVGLNLKAPKLKTDVDVSLPKVEGDLKGPEIDVKAPKM
  DVNVGDIDIEGPEGKLKGPKFKMPEMHFKAPKISMPDVDLHLKGPKVKGDMDVSVPKVEG
  EMKVPDVDIKGPKVDIDAPDVEVHDPDWHLKMPKMKMPKFSMPGFKAEGPEVDVNLPKAD
  IDVSGPSVDTDAPDLDIEGPEGKLKGSKFKMPKLNIKAPKVSMPDVDLNLKGPKLKGEID
  ASVPELEGDLRGPQVDVKGPFVEAEVPDVDLECPDAKLKGPKFKMPEMHFKAPKISMPDV
  DLHLKGPKVKGDADVSVPKLEGDLTGPSVGVEVPDVELECPDAKLKGPKFKMPDMHFKAP
  KISMPDVDLHLKGPKVKGDVDVSVPKLEGDLTGPSVGVEVPDVELECPDAKLKGPKFKMP
  EMHFKTPKISMPDVDLHLKGPKVKGDMDVSVPKVEGEMKVPDVDIKGPKMDIDAPDVDVH
  GPDWHLKMPKMKMPKFSMPGFKAEGPEVDVNLPKADVVVSGPKVDVEVPDVSLEGPEGKL
  KGPKLKMPEMHFKAPKISMPDVDLHLKGPKVKGDVDVSLPKLEGDLTGPSVDVEVPDVEL
  ECPDAKLKGPKFKMPEMHFKTPKISMPDVNLNLKGPKVKGDMDVSVPKVEGEMKVPDVDI
  RGPKVDIDAPDVDVHGPDWHLKMPKMKMPKFSMPGFKGEGPEVDVNLPKADVDVSGPKVD
  VEVPDVSLEGPEGKLKGPKFKMPEMHFKTPKISMPDVDFNLKGPKIKGDVDVSAPKLEGE
  LKGPELDVKGPKLDADMPEVAVEGPNGKWKTPKFKMPDMHFKAPKISMPDLDLHLKSPKA
  KGEVDVDVPKLEGDLKGPHVDVSGPDIDIEGPEGKLKGPKFKMPDMHFKAPNISMPDVDL
  NLKGPKIKGDVDVSVPEVEGKLEVPDMNIRGPKVDVNAPDVQAPDWHLKMPKMKMPKFSM
  PGFKAEGPEVDVNLPKADVDISGPKVDIEGPDVNIEGPEGKLKGPKLKMPEMNIKAPKIS
  MPDFDLHLKGPKVKGDVDVSLPKVEGDLKGPEVDIKGPKVDINAPDVGVQGPDWHLKMPK
  VKMPKFSMPGFKGEGPDGDVKLPKADIDVSGPKVDIEGPDVNIEGPEGKLKGPKFKMPEM
  NIKAPKISMPDIDLNLKGPKVKGDVDVSLPKVEGDLKGPEVDIKGPKVDIDAPDVDVHGP
  DWHLKMPKIKMPKISMPGFKGEGPDVDVNLPKADIDVSGPKVDVECPDVNIEGPEGKWKS
  PKFKMPEMHFKTPKISMPDIDLNLTGPKIKGDVDVTGPKVEGDLKGPEVDLKGPKVDIDV
  PDVNVQGPDWHLKMPKMKMPKFSMPGFKAEGPEVDVNLPKADVDVSGPKVDVEGPDVNIE
  GPEGKLKGPKFKMPEMNIKAPKIPMPDFDLHLKGPKVKGDVDISLPKVEGDLKGPEVDIR
  GPQVDIDVPDVGVQGPDWHLKMPKVKMPKFSMPGFKGEGPDVDVNLPKADLDVSGPKVDI
  DVPDVNIEGPEGKLKGPKFKMPEMNIKAPKISMPDIDLNLKGPKVKGDMDVSLPKVEGDM
  KVPDVDIKGPKVDINAPDVDVQGPDWHLKMPKIKMPKISMPGFKGEGPEVDVNLPKADLD
  VSGPKVDVDVPDVNIEGPDAKLKGPKFKMPEMNIKAPKISMPDLDLNLKGPKMKGEVDVS
  LANVEGDLKGPALDIKGPKIDVDAPDIDIHGPDAKLKGPKLKMPDMHVNMPKISMPEIDL
  NLKGSKLKGDVDVSGPKLEGDIKAPSLDIKGPEVDVSGPKLNIEGKSKKSRFKLPKFNFS
  GSKVQTPEVDVKGKKPDIDITGPKVDINAPDVEVQGKVKGSKFKMPFLSISSPKVSMPDV
  ELNLKSPKVKGDLDIAGPNLEGDFKGPKVDIKAPEVNLNAPDVDVHGPDWNLKMPKMKMP
  KFSVSGLKAEGPDVAVDLPKGDINIEGPSMNIEGPDLNVEGPEGGLKGPKFKMPDMNIKA
  PKISMPDIDLNLKGPKVKGDVDISLPKLEGDLKGPEVDIKGPKVDINAPDVDVHGPDWHL
  KMPKVKMPKFSMPGFKGEGPEVDVTLPKADIDISGPNVDVDVPDVNIEGPDAKLKGPKFK
  MPEMNIKAPKISMPDFDLNLKGPKMKGDVVVSLPKVEGDLKGPEVDIKGPKVDIDTPDIN
  IEGSEGKFKGPKFKIPEMHLKAPKISMPDIDLNLKGPKVKGDVDVSLPKMEGDLKGPEVD
  IKGPKVDINAPDVDVQGPDWHLKMPKVKMPKFSMPGFKGEGPDVDVNLPKADLDVSGPKV
  DIDVPDVNIEGPEGKLKGPKFKMPEMNIKAPKISMPDIDLNLKGPKVKGDMDVSLPKVEG
  DMQVPDLDIKGPKVDINAPDVDVRGPDWHLKMPKIKMPKISMPGFKGEGPEVDVNLPKAD
  LDVSGPKVDVDVPDVNIEGPDAKLKGPKFKMPEMNIKAPKISMPDFDLHLKGPKVKGDVD
  VSLPKMEGDLKAPEVDIKGPKVDIDAPDVDVHGPDWHLKMPKVKMPKFSMPGFKGEGPEV
  DVNLPKADIDVSGPKVDIDTPDIDIHGPEGKLKGPKFKMPDLHLKAPKISMPEVDLNLKG
  PKMKGDVDVSLPKVEGDLKGPEVDIKGPKVDIDVPDVDVQGPDWHLKMPKVKMPKFSMPG
  FKGEGPDVDVNLPKADLDVSGPKVDIDVPDVNIEGPDAKLKGPKFKMPEMNIKAPKISMP
  DFDLHLKGPKVKGDVDVSLPKVEGDLKGPEVDIKGPKVDIDAPDVDVHGPDWHLKMPKVK
  MPKFSMPGFKGEGPDVDVTLPKADIEISGPKVDIDAPDVSIEGPDAKLKGPKFKMPEMNI
  KAPKISMPDIDFNLKGPKVKGDVDVSLPKVEGDLKGPEIDIKGPSLDIDTPDVNIEGPEG
  KLKGPKFKMPEMNIKAPKISMPDFDLHLKGPKVKGDVDVSLPKVESDLKGPEVDIEGPEG
  KLKGPKFKMPDVHFKSPQISMSDIDLNLKGPKIKGDMDISVPKLEGDLKGPKVDVKGPKV
  GIDTPDIDIHGPEGKLKGPKFKMPDLHLKAPKISMPEVDLNLKGPKVKGDMDISLPKVEG
  DLKGPEVDIRDPKVDIDVPDVDVQGPDWHLKMPKVKMPKFSMPGFKGEGPDVDVNLPKAD
  IDVSGPKVDVDVPDVNIEGPDAKLKGPKFKMPEMSIKAPKISMPDIDLNLKGPKVKGDVD
  VTLPKVEGDLKGPEADIKGPKVDINTPDVDVHGPDWHLKMPKVKMPKFSMPGFKGEGPDV
  DVSLPKADIDVSGPKVDVDIPDVNIEGPDAKLKGPKFKMPEINIKAPKISIPDVDLDLKG
  PKVKGDFDVSVPKVEGTLKGPEVDLKGPRLDFEGPDAKLSGPSLKMPSLEISAPKVTAPD
  VDLHLKAPKIGFSGPKLEGGEVDLKGPKVEAPSLDVHMDSPDINIEGPDVKIPKFKKPKF
  GFGAKSPKADIKSPSLDVTVPEAELNLETPEISVGGKGKKSKFKMPKIHMSGPKIKAKKQ
  GFDLNVPGGEIDASLKAPDVDVNIAGPDAALKVDVKSPKTKKTMFGKMYFPDVEFDIKSP
  KFKAEAPLPSPKLEGELQAPDLELSLPAIHVEGLDIKAKAPKVKMPDVDISVPKIEGDLK
  GPKVQANLGAPDINIEGLDAKVKTPSFGISAPQVSIPDVNVNLKGPKIKGDVPSVGLEGP
  DVDLQGPEAKIKFPKFSMPKIGIPGVKMEGGGAEVHAQLPSLEGDLRGPDVKLEGPDVSL
  KGPGVDLPSVNLSMPKVSGPDLDLNLKGPSLKGDLDASVPSMKVHAPGLNLSGVGGKMQV
  GGDGVKVPGIDATTKLNVGAPDVTLRGPSLQGDLAVSGDIKCPKVSVGAPDLSLEASEGS
  IKLPKMKLPQFGISTPGSDLHVNAKGPQVSGELKGPGVDVNLKGPRISAPNVDFNLEGPK
  VKGSLGATGEIKGPTVGGGLPGIGVQGLEGNLQMPGIKSSGCDVNLPGVNVKLPTGQISG
  PEIKGGLKGSEVGFHGAAPDISVKGPAFNMASPESDFGINLKGPKIKGGADVSGGVSAPD
  ISLGEGHLSVKGSGGEWKGPQVSSALNLDTSKFAGGLHFSGPKVEGGVKGGQIGLQAPGL
  SVSGPQGHLESGSGKVTFPKMKIPKFTFSGRELVGREMGVDVHFPKAEASIQAGAGDGEW
  EESEVKLKKSKIKMPKFNFSKPKGKGGVTGSPEASISGSKGDLKSSKASLGSLEGEAEAE
  ASSPKGKFSLFKSKKPRHRSNSFSDEREFSGPSTPTGTLEFEGGEVSLEGGKVKGKHGKL
  KFGTFGGLGSKSKGHYEVTGSDDETGKLQGSGVSLASKKSRLSSSSSNDSGNKVGIQLPE
  VELSVSTKKE
• Function: May be required for neuronal cell differentiation.
• KEGG Pathway: Salmonella infection (hsa05132)

Molecular Interaction Atlas (MIA) of This DOT

33 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Bladder transitional cell carcinoma	DISNL46A	Definitive	Biomarker	[1]
Alzheimer disease	DISF8S70	Strong	Genetic Variation	[2]
Androgen insensitivity syndrome	DISUZBBO	Strong	Biomarker	[3]
Autoimmune disease	DISORMTM	Strong	Biomarker	[4]
Breast cancer	DIS7DPX1	Strong	Biomarker	[5]
Breast carcinoma	DIS2UE88	Strong	Biomarker	[5]
Clear cell renal carcinoma	DISBXRFJ	Strong	Biomarker	[6]
Glioma	DIS5RPEH	Strong	Altered Expression	[7]
Hepatocellular carcinoma	DIS0J828	Strong	Biomarker	[8]
Metastatic malignant neoplasm	DIS86UK6	Strong	Biomarker	[5]
Neoplasm	DISZKGEW	Strong	Biomarker	[9]
Papillary renal cell carcinoma	DIS25HBV	Strong	Biomarker	[6]
Renal cell carcinoma	DISQZ2X8	Strong	Biomarker	[6]
Rheumatoid arthritis	DISTSB4J	Strong	Biomarker	[4]
Systemic lupus erythematosus	DISI1SZ7	Strong	Biomarker	[4]
Triple negative breast cancer	DISAMG6N	Strong	Biomarker	[10]
Lung adenocarcinoma	DISD51WR	Disputed	Altered Expression	[11]
Lung cancer	DISCM4YA	Disputed	Biomarker	[11]
Lung carcinoma	DISTR26C	Disputed	Biomarker	[11]
Lung neoplasm	DISVARNB	Disputed	Biomarker	[11]
Adult glioblastoma	DISVP4LU	Limited	Biomarker	[9]
Advanced cancer	DISAT1Z9	Limited	Biomarker	[12]
Asthma	DISW9QNS	Limited	Genetic Variation	[13]
Carcinoma of liver and intrahepatic biliary tract	DIS8WA0W	Limited	Posttranslational Modification	[14]
Castration-resistant prostate carcinoma	DISVGAE6	Limited	Altered Expression	[15]
Glioblastoma multiforme	DISK8246	Limited	Biomarker	[9]
Hepatitis B virus infection	DISLQ2XY	Limited	Posttranslational Modification	[14]
Liver cancer	DISDE4BI	Limited	Posttranslational Modification	[14]
Matthew-Wood syndrome	DISA7HR7	Limited	Biomarker	[12]
Melanoma	DIS1RRCY	Limited	Biomarker	[16]
Mesothelioma	DISKWK9M	Limited	Biomarker	[17]
Metastatic melanoma	DISSL43L	Limited	Genetic Variation	[16]
Pancreatic adenocarcinoma	DISKHX7S	Limited	Biomarker	[12]

31 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[18]
Tretinoin	DM49DUI	Approved	Tretinoin decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[20]
Acetaminophen	DMUIE76	Approved	Acetaminophen decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[21]
Doxorubicin	DMVP5YE	Approved	Doxorubicin increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[22]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[23]
Cisplatin	DMRHGI9	Approved	Cisplatin decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[24]
Estradiol	DMUNTE3	Approved	Estradiol increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[25]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[26]
Temozolomide	DMKECZD	Approved	Temozolomide decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[28]
Calcitriol	DM8ZVJ7	Approved	Calcitriol increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[29]
Testosterone	DM7HUNW	Approved	Testosterone increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[29]
Decitabine	DMQL8XJ	Approved	Decitabine affects the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[30]
Fluorouracil	DMUM7HZ	Approved	Fluorouracil decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[31]
Panobinostat	DM58WKG	Approved	Panobinostat increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[32]
Fulvestrant	DM0YZC6	Approved	Fulvestrant decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[25]
Demecolcine	DMCZQGK	Approved	Demecolcine increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[33]
Cytarabine	DMZD5QR	Approved	Cytarabine decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[34]
Urethane	DM7NSI0	Phase 4	Urethane increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[35]
SNDX-275	DMH7W9X	Phase 3	SNDX-275 increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[36]
Tamibarotene	DM3G74J	Phase 3	Tamibarotene decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[20]
Amiodarone	DMUTEX3	Phase 2/3 Trial	Amiodarone increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[37]
Tocopherol	DMBIJZ6	Phase 2	Tocopherol increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[38]
Afimoxifene	DMFORDT	Phase 2	Afimoxifene decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[25]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the mutagenesis of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[39]
Leflunomide	DMR8ONJ	Phase 1 Trial	Leflunomide decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[40]
THAPSIGARGIN	DMDMQIE	Preclinical	THAPSIGARGIN increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[42]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[43]
Trichostatin A	DM9C8NX	Investigative	Trichostatin A increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[44]
Milchsaure	DM462BT	Investigative	Milchsaure increases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[45]
methyl p-hydroxybenzoate	DMO58UW	Investigative	methyl p-hydroxybenzoate decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[46]
KOJIC ACID	DMP84CS	Investigative	KOJIC ACID decreases the expression of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[48]

6 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Ciclosporin	DMAZJFX	Approved	Ciclosporin decreases the methylation of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[19]
Quercetin	DM3NC4M	Approved	Quercetin decreases the phosphorylation of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[27]
TAK-243	DM4GKV2	Phase 1	TAK-243 affects the sumoylation of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[41]
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 affects the phosphorylation of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[27]
Coumarin	DM0N8ZM	Investigative	Coumarin affects the phosphorylation of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[27]
Hexadecanoic acid	DMWUXDZ	Investigative	Hexadecanoic acid decreases the phosphorylation of Neuroblast differentiation-associated protein AHNAK (AHNAK).	[47]

References

• [1] Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology.Mol Cell Proteomics. 2018 Sep;17(9):1788-1802. doi: 10.1074/mcp.RA118.000562. Epub 2018 Jun 27.
• [2] Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3.Mol Psychiatry. 2016 Nov;21(11):1608-1612. doi: 10.1038/mp.2015.218. Epub 2016 Feb 2.
• [3] Alterations of the gut microbiome and plasma proteome in Chinese patients with adolescent idiopathic scoliosis.Bone. 2019 Mar;120:364-370. doi: 10.1016/j.bone.2018.11.017. Epub 2018 Nov 24.
• [4] Identification of AHNAK as a novel autoantigen in systemic lupus erythematosus.Biochem Biophys Res Commun. 2002 Mar 8;291(4):951-8. doi: 10.1006/bbrc.2002.6534.
• [5] Doxorubicin resistance in breast cancer: A novel role for the human protein AHNAK.Biochem Pharmacol. 2018 Feb;148:174-183. doi: 10.1016/j.bcp.2018.01.012. Epub 2018 Jan 5.
• [6] Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma.Nat Genet. 2011 Dec 4;44(1):17-9. doi: 10.1038/ng.1014.
• [7] AHNAK as a Prognosis Factor Suppresses the Tumor Progression in Glioma.J Cancer. 2017 Aug 25;8(15):2924-2932. doi: 10.7150/jca.20277. eCollection 2017.
• [8] Overexpression of RNF38 facilitates TGF- signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma.J Exp Clin Cancer Res. 2019 Mar 5;38(1):113. doi: 10.1186/s13046-019-1113-3.
• [9] Paucimannosidic glycoepitopes inhibit tumorigenic processes in glioblastoma multiforme.Oncotarget. 2019 Jul 9;10(43):4449-4465. doi: 10.18632/oncotarget.27056. eCollection 2019 Jul 9.
• [10] AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.J Exp Clin Cancer Res. 2017 May 12;36(1):65. doi: 10.1186/s13046-017-0522-4.
• [11] AHNAK Loss in Mice Promotes Type II Pneumocyte Hyperplasia and Lung Tumor Development.Mol Cancer Res. 2018 Aug;16(8):1287-1298. doi: 10.1158/1541-7786.MCR-17-0726. Epub 2018 May 3.
• [12] Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transition.J Cancer. 2019 Jun 10;10(16):3860-3870. doi: 10.7150/jca.31291. eCollection 2019.
• [13] Evaluation of a partial genome screening of two asthma susceptibility regions using bayesian network based bayesian multilevel analysis of relevance.PLoS One. 2012;7(3):e33573. doi: 10.1371/journal.pone.0033573. Epub 2012 Mar 14.
• [14] Distinctive pattern of AHNAK methylation level in peripheral blood mononuclear cells and the association with HBV-related liver diseases.Cancer Med. 2018 Oct;7(10):5178-5186. doi: 10.1002/cam4.1778. Epub 2018 Sep 27.
• [15] BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK.Mol Cancer Res. 2019 Aug;17(8):1627-1638. doi: 10.1158/1541-7786.MCR-18-1279. Epub 2019 May 20.
• [16] AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1.Melanoma Res. 2016 Apr;26(2):108-16. doi: 10.1097/CMR.0000000000000228.
• [17] AHNAK is highly expressed and plays a key role in cell migration and invasion in mesothelioma.Int J Oncol. 2014 Feb;44(2):530-8. doi: 10.3892/ijo.2013.2183. Epub 2013 Nov 20.
• [18] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [19] Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
• [20] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [21] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [22] Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
• [23] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [24] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [25] Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells. J Cell Biochem. 2006 Aug 1;98(5):1163-84.
• [26] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [27] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [28] Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
• [29] Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
• [30] Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS One. 2012;7(12):e53003. doi: 10.1371/journal.pone.0053003. Epub 2012 Dec 27.
• [31] Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer. 2004 Nov 1;112(2):200-12. doi: 10.1002/ijc.20401.
• [32] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [33] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [34] Cytosine arabinoside induces ectoderm and inhibits mesoderm expression in human embryonic stem cells during multilineage differentiation. Br J Pharmacol. 2011 Apr;162(8):1743-56.
• [35] Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
• [36] Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
• [37] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [38] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [39] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [40] Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
• [41] Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies. J Biol Chem. 2019 Oct 18;294(42):15218-15234. doi: 10.1074/jbc.RA119.009147. Epub 2019 Jul 8.
• [42] The genome-wide expression profile of Scrophularia ningpoensis-treated thapsigargin-stimulated U-87MG cells. Neurotoxicology. 2009 May;30(3):368-76.
• [43] Bisphenolic compounds alter gene expression in MCF-7 cells through interaction with estrogen receptor . Toxicol Appl Pharmacol. 2020 Jul 15;399:115030. doi: 10.1016/j.taap.2020.115030. Epub 2020 May 6.
• [44] From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
• [45] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [46] Transcriptome dynamics of alternative splicing events revealed early phase of apoptosis induced by methylparaben in H1299 human lung carcinoma cells. Arch Toxicol. 2020 Jan;94(1):127-140. doi: 10.1007/s00204-019-02629-w. Epub 2019 Nov 20.
• [47] Functional lipidomics: Palmitic acid impairs hepatocellular carcinoma development by modulating membrane fluidity and glucose metabolism. Hepatology. 2017 Aug;66(2):432-448. doi: 10.1002/hep.29033. Epub 2017 Jun 16.
• [48] Toxicogenomics of kojic acid on gene expression profiling of a375 human malignant melanoma cells. Biol Pharm Bull. 2006 Apr;29(4):655-69.